Eli Lilly & Co. is in the running to bring a fourth interleukin-23 (IL-23) inhibitor to market and reported Phase II results on 21 May for its candidate mirikizumab in Crohn's disease. It's the second inflammatory bowel disease (IBD) that Lilly's pursuing, in addition to ulcerative colitis – a pair of indications that could give it an edge in a crowded IL-23 field, though competitors also are moving ahead in the space.
Lotus Mallbris, vice president of immunology development, told Scrip that while gastroenterology is a relatively new therapeutic area for Lilly, the company worked with doctors and patients to design a clinical trial program that reflects current thinking in Crohn's treatment and attempts to address unmet needs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?